| GTAB SUMMARY | GTAB SUMMARY | GTAB SUMMARY |\n| **CLINICAL INFORMATION (include any treatment history and standard-of-care testing**  **already performed):**  Diagnosis:  pT2bN0M1 LV-PN-R0 squamous cell carcinoma lung  Treatment:  •	Lobectomy 07/8/22  •	Completed 8 cycles adjuvant carboplatin-paclitaxel 12/02/23  •	Adjuvant chemoRT completed 15/04/23  •	May 2024 - possible liver mets  •	September 2024 - definitive progressive liver mets, commenced pembrolizumab monotherapy  •	March 25 - completed 4 cycles with partial response  •	17/6/25- progressive liver mets  **FAMILY HISTORY:**  Father AML  Mother thyroid ca - early 70s  Brother - lung cancer age early 60s  Maternal uncle kidney ca in 60s  Maternal grandmother cervical ca in 80s  Maternal grandfather lung ca in 70s  ?had genetics referral but no formal  *Lynch*  testing  **QUESTION(S) FOR GTAB:**  DESTINY trial referral  Review of potential pathogenic germline variant  Review of potential somatic variant  Eligibility for clinical trials | | | |\n| **SOMATIC FINDINGS (including gene name, variant and allele frequency):**  **FoundationOne®Liquid CDx:**  | Gene | Alteration | VAF (%) | |---------|--------------|-----------| | TET2 | R1261fs*15 | 0.73% | | FGFR2 | S252W | 42.7% |  **ADDITIONAL FINDINGS (including Tumour Mutational Burden and MSI status):**  TMB: 3 Muts/Mb  MSI status: MSI-High Not Detected  Tumour fraction: Low (< 1.0%)  **FoundationOne®RNA:**  | Gene | Alteration | VAF (%) | |---------|------------------------|------------------------| | RB1 | loss | loss | | PTEN | loss | loss | | EGFR | L858R | 18.92% | | NF1 | rearrangement intron 4 | rearrangement intron 4 | | FGFR2 | S252W | 61.23% | | APC | loss | loss | | BRAF | V600E*2 | 28.76% |  **ADDITIONAL FINDINGS (including Tumour Mutational Burden and MSI status):**  TMB: 5 Muts/Mb  MSI status: MS-Stable  Tumour fraction/cellularity: Not detected  HRD signature: HRDsig Negative (0.12) | | | |\n| **ADDITIONAL GERMLINE FINDINGS (including Cancer Pertinent Germline Susceptibility):**  No germline testing undertaken, tumour-only testing performed. | | | |\n| **GTAB RECOMMENDATIONS (including actions and owners):**  Likely oncogenic  *RB1*  loss and  *NF1*  rearrangement  For consideration of potential clinical trial (listed below) if clinically appropriate, eligibility criteria met and if still actively recruiting.  A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BMS 825 alone and in combination with nivolumab in subjects with advanced NF1 null solid tumors  https://clinicaltrials.gov/study/NCT06182947  ClinicalTrials.gov  Open to recruitment at UCLH  [chris.pinenut@nhs.net](mailto:chris.pinenut@nhs.net) | | | |